Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy
<p>Abstract</p> <p>Background</p> <p>Prior research has demonstrated that medication persistence (continued acquisition of therapy over time) is far from optimal among patients with glaucoma. The purpose of the present study was to evaluate persistence with prostaglandi...
Main Authors: | Schwartz Gail F, Reardon Gregory, Kotak Sameer |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-03-01
|
Series: | BMC Ophthalmology |
Online Access: | http://www.biomedcentral.com/1471-2415/10/5 |
Similar Items
-
Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: Retrospective analysis of three medical/pharmacy claims databases
by: Kotak Sameer, et al.
Published: (2011-06-01) -
Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review
by: Reardon G, et al.
Published: (2011-09-01) -
Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
by: Kenji Inoue, et al.
Published: (2011-03-01) -
Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
by: Michael B Horsley, et al.
Published: (2009-03-01) -
Ocular hypotensive effects of prostaglandin analogs in Japanese patients with normal-tension glaucoma: a literature review
by: Takagi Y, et al.
Published: (2018-09-01)